More than 1 billion people worldwide live with obesity, a prevalence that is expected to double by 2035. Type 2 diabetes and obesity are strictly interconnected, with almost 80% of people affected by type 2 diabetes having also obesity.1 New anti-diabetic medications can induce a meaningful weight loss, at an average of 11 kg (–12% change from baseline) with tirzepatide 15 mg and 6 kg (–6% change from baseline) with semaglutide 1 mg subcutaneously on a weekly basis
Patient-reported outcome measures after metabolic surgery / Mingrone, Geltrude; Castagneto-Gissey, Lidia; Stefan, R Bornstein. - In: THE LANCET DIABETES & ENDOCRINOLOGY. - ISSN 2213-8587. - (2023).
Patient-reported outcome measures after metabolic surgery
Lidia Castagneto-GisseySecondo
;
2023
Abstract
More than 1 billion people worldwide live with obesity, a prevalence that is expected to double by 2035. Type 2 diabetes and obesity are strictly interconnected, with almost 80% of people affected by type 2 diabetes having also obesity.1 New anti-diabetic medications can induce a meaningful weight loss, at an average of 11 kg (–12% change from baseline) with tirzepatide 15 mg and 6 kg (–6% change from baseline) with semaglutide 1 mg subcutaneously on a weekly basisI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
